Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Coronaviruses (CoVs) belong to the Coronaviridae-family. The genus Beta-coronaviruses, are enveloped positive strand RNA viruses with club-like spikes at the surface with a unique replication process and a large RNA genome (∼25 kb). CoVs are known as one of the major pathogenic viruses causing a variety of diseases in birds and mammals including humans (lethal respiratory dysfunctions). Recently, a new strain of coronavirus has been identified and named as SARS-CoV-2. A large number of COVID-19 (disease caused by SARS-CoV-2) cases are being diagnosed all over the World especially in China (Wuhan). COVID-19 showed high mortality rate exponentially, however, not even a single effective cure is being introduced yet against COVID-19. In the current study, immunoinformatics approaches were employed to predict the antigenic epitopes against COVID-19 for the development of a coronavirus peptide vaccine. Cytotoxic T-lymphocyte (CTL) and B-cell epitopes were predicted for SARS-CoV-2 coronavirus structural proteins (Spikes, Membrane, Envelope, and Nucleocapsid). The docking complexes of the top 10 epitopes having antigenic sites were analyzed led by binding affinity and binding interactional analyses of top ranked predicted peptides with the MHC-I HLA molecule. The predicted peptides may have potential to be used as peptide vaccine against COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593713 | PMC |
| http://dx.doi.org/10.3389/fmolb.2020.00227 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.
Best Pract Res Clin Haematol
September 2025
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA; Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, USA.
Immunotherapy, including immune checkpoint blockade, CART cells and bispecific antibodies have resulted in dramatic improvements in outcomes for patients with hematological malignancies, demonstrating the unique potency of the immune system in targeting malignant cells. The development of cancer vaccines aims to evoke an activated effector cell population and a memory response to provide long term immune surveillance to protect from relapse. Developing a potent cancer vaccine relies on identifying appropriate antigen targets, enhancing antigen presentation, and overcoming the immune suppressive milieu of the micro-environment.
View Article and Find Full Text PDFComputational identification of membrane proteins for vaccine design against drug-resistant Moraxella catarrhalis.
Mol Genet Genomics
September 2025
Department of Biochemistry, Bahauddin Zakariya University, Multan, Multan, 66000, Punjab, Pakistan.
Moraxella catarrhalis is a Gram-negative diplococcus bacterium and a common respiratory pathogen, implicated in 15-20% of otitis media (OM) cases in children and chronic obstructive pulmonary disease (COPD) in adults. The rise of drug-resistant Moraxella catarrhalis has highlighted the urgent need for the potent vaccine strategies to reduce its clinical burden. Despite a mortality rate of 13%, there is no FDA-approved vaccine for this pathogen.
View Article and Find Full Text PDFEngineering a recombinant VP2-Based neutralizing epitope vaccine candidate against canine parvovirus: a preliminary immunogenicity assessment.
Vet Res Commun
September 2025
Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin, 150030, China.
Background: Canine parvovirus (CPV) poses a severe threat to canine health, necessitating the development of safer and more effective vaccines. While traditional vaccines carry risks of virulence reversion and environmental contamination, subunit vaccines-especially neutralizing epitope vaccines-offer promising alternatives by eliciting targeted immune responses with enhanced safety.
Methods: We employed bacterial display technology to express 11 overlapping CPV VP2 gene fragments on the periplasmic membrane of E.
Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity.
PLoS One
September 2025
Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Vaccines of enhanced range of protection could help to control newly emerging infectious diseases while providing greater resilience to any subsequent variants. Such "universal vaccines" are an idealized, but unrealized, goal that may benefit from unbiased, high-throughput approaches that define antibody cross-reactivity to enable rational selection of cross-protective epitopes. The priority of this investigation is to establish a pipeline for the identification and preliminary characterization of epitopes with enhanced cross-reactivity.
View Article and Find Full Text PDFProtein A-like peptide generation based on generalized diffusion model.
J Comput Aided Mol Des
September 2025
College of Information Engineering, Beijing Institute of Petrochemical Technology, No. 19 Qingyuan North Road, Daxing District, Beijing, 102617, China.
With the rapid advancement of biotechnology, protein generation and design based on generative models have demonstrated extensive applications in drug development, vaccine research, and biocatalysis. This research proposes a protein generation method based on the generalized diffusion model, which breaks through the traditional diffusion model's reliance on Gaussian noise, enables more flexible protein sequence generation, and preliminarily verifies its advantages. Specifically, protein sequences were first encoded using one-hot encoding and input into the diffusion model to generate novel sequences.
View Article and Find Full Text PDF